A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)

PHASE3CompletedINTERVENTIONAL
Enrollment

604

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

May 31, 2005

Study Completion Date

May 31, 2005

Conditions
Crohn's Disease
Interventions
DRUG

Certolizumab Pegol (CDP870)

Sponsors

Lead Sponsor

All Listed Sponsors
lead

UCB Pharma

INDUSTRY